Revenue: $188.8 million for Q1 2025, up from $25.3 million in Q1 2024. Cash and Marketable Securities: Approximately $954 million as of March 31, 2025. General and Administrative Expenses: $26.6 million for Q1 2025, compared to $24.3 million in Q1 2024. Research and Development Expenses: $90.8 million for Q1 2025, up from $84.3 million in
Stocks to buy: Ahead of the market opening on Thursday i.e. January 9, brokerage HDFC Securities picked five stocks. These are – Intellect Design Arena, Westlife Foodworld, Ajanta Pharma, Pfizer, and Minda Corporation. It has given targets for these stocks for up to three months. Know brokerage ratings, target prices, and stop losses for these
AstraZeneca on Wednesday convinced a federal judge in Delaware to throw out a jury’s decision that the company owes $107.5 million for infringing cancer-drug patents belonging to Pfizer subsidiary Wyeth. U.S. District Judge Matthew Kennelly determined that the two patents Pfizer accused AstraZeneca of infringing with its blockbuster lung-cancer drug Tagrisso were invalid. Spokespeople for